Targeting EZH2 to improve treatment for aggressive leukemia
Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in caner
This study is looking at how a protein called EZH2 affects aggressive leukemia, especially in cases with specific gene changes, and is testing a new way to target and break down this protein to help create better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11016927 on NIH RePORTER |
What this research studies
This research investigates the role of EZH2, a protein involved in gene regulation, in aggressive forms of leukemia, particularly those with MLL1 rearrangements. The study aims to develop new treatment strategies using a novel technology called Proteolysis Targeting Chimera (PROTAC) to degrade EZH2 and its partners, which may contribute to cancer progression. By targeting both the canonical and non-canonical functions of EZH2, the research seeks to enhance the effectiveness of leukemia treatments and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with MLL1-rearranged acute leukemia who have limited treatment options.
Not a fit: Patients with leukemia types not associated with MLL1 rearrangements may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with aggressive leukemia, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in targeting EZH2 in cancer, but this approach using PROTAC technology is relatively novel and untested in this specific context.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Wang, G Greg — Duke University
- Study coordinator: Wang, G Greg
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.